Economia
Transgene to Showcase Potential of Proprietary VacDesignR® Computational Tool to Optimize Individualized Therapeutic Cancer Vaccines
Computational tool improves recombinant virus design efficiency and yield.
This innovative in-house development is a key component of Transgene’s INTV platform.
Poster to be presented at ESMO-AI 2025
Strasbourg, France, November 6, 2025, 8:30 a.m. CET – a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer today announced it will conference, held in Berlin, Germany, from 12-14 November 2025.
The presentation will highlight how , enabling faster and more reliable manufacturing of individualized neoantigen therapeutic vaccines ( ).
The individualized immunotherapies developed through the ® platform, currently being evaluated in a Phase I/II clinical trial (NCT04183166 ) , are based on an MVA viral vector and their design already leverages the VacDesignR® tool.
Developed in-house, , a core component of Transgene’s ® platform. By minimizing unwanted homologous recombination and intelligently selecting peptide sequences for cassette assembly, VacDesignR® significantly improves production reliability and vector quality.
Future iterations of to further improve performance and scalability, supporting Transgene’s strategy to accelerate production timelines for individualized therapeutic vaccines, including its lead candidate TG4050 designed to treat HPV-negative head and neck cancers following surgery and adjuvant therapy.
commented .
The poster presentation will take place on at ESMO-AI conference and will be available that day on Transgene’s website.
VacDesignR® is a computer-assisted method protected through patent and patent applications derived from WO2021/130210.
***
Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. The Company’s clinical-stage programs consist of a portfolio of viral vector-based immunotherapeutics. TG4050, the first individualized therapeutic vaccine based on the ® platform is the Company’s lead asset, with demonstrated proof of principle in patients in the adjuvant treatment of head and neck cancers. The Company has other viral vector-based assets, including BT-001, an oncolytic virus based on the Invir.IO® viral backbone, which is in clinical development. The Company also conducts innovative discovery and preclinical work, aimed at developing novel viral vector-based modalities.
With Transgene’s ® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The
® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations, identified and selected through advanced Artificial Intelligence technologies.
With its proprietary platform Invir.IO®, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses.
Additional information about Transgene is available at: www.transgene.com
Follow us on social media: X (formerly Twitter): @TransgeneSA — LinkedIn: @Transgene — Bluesky: @Transgene
® is a viral vector (MVA – Modified Vaccinia Ankara) based, individualized immunotherapy platform that has been developed by Transgene to target solid tumors.
®-derived products are designed to stimulate the patient’s immune system to recognize and destroy tumors using their own cancer specific genetic mutations. Transgene has set up an innovative network that combines bioengineering, digital transformation, established vectorization know-how and unique manufacturing capabilities. Transgene has been awarded “Investment for the Future” funding from Bpifrance for the development of its platform
®. TG4050 is the first ®-derived product being evaluated in clinical trials. Click here to watch a short video on
c®.
Individualized Therapeutic Neoantigen Vaccine
Attachment
2321 Rosecrans Avenue. Suite 2200
90245 El Segundo Stati Uniti